Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

16:08
10/09/16
10/09
16:08
10/09/16
16:08

Merck reports 18-month data from KEYNOTE-010, other Keytruda data sets

Merck announced that Keytruda demonstrated superiority in overall survival at 18 months compared to standard of care chemotherapy -- docetaxel -- in patients with metastatic non-small cell lung cancer previously treated with platinum-containing chemotherapy whose tumors expressed PD-L1, as well as patients with high levels of PD-L1 expression. The data, from the phase 2/3 KEYNOTE-010 trial, will be presented at the ESMO 2016 Congress. In addition, an analysis of patient-reported health-related quality of life outcomes showed more patients treated with Keytruda reported positive outcomes compared to patients treated with chemotherapy. Separately, researchers also presented an analysis of PD-L1 prevalence across three separate studies, including KEYNOTE-010. Overall, 66 percent of patients with metastatic NSCLC expressed any level of PD-L1, and 28 percent expressed high levels of PD-L1. Specifically, the new data from KEYNOTE-010 included six months of additional follow-up, with a median follow-up of 19.2 months, and showed superior outcomes of OS, PFS, and ORR with Keytruda compared to docetaxel in patients with PD-L1 expression as well as high levels of PD-L1 expression -- with consistency of outcomes across Keytruda doses. In patients with PD-L1 expression, OS at 18 months was 37 percent with Keytruda 2 mg/kg, 43 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. Among all patients, median OS was 10.5 months with Keytruda 2 mg/kg, 13.6 months with Keytruda 10 mg/kg, and 8.6 months with docetaxel. ORR was 19 percent with Keytruda 2 mg/kg, 20 percent with Keytruda 10 mg/kg and 10 percent with docetaxel. Responses to Keytruda continued to be durable; among patients with any level of PD-L1 expression who responded to treatment, 60 percent on each of the Keytruda treatment arms were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. In patients with high levels of PD-L1 expression, OS at 18 months was 46 percent with Keytruda 2 mg/kg, 52 percent with Keytruda 10 mg/kg, and 24 percent with docetaxel. In this group, median OS was 15.8 months with Keytruda 2 mg/kg, 18.8 months with Keytruda 10 mg/kg, and 8.2 months with docetaxel. ORR was 29 percent with Keytruda 2 mg/kg, 32 percent with Keytruda 10 mg/kg, and nine percent with docetaxel. Responses to Keytruda continued to be durable; among patients with high levels of PD-L1 expression who responded to treatment, 68 and 63 percent on the Keytruda 2 mg/kg and 10 mg/kg treatment arms, respectively, were alive, progression-free, and had not received additional therapy for their disease, compared to 15 percent in the docetaxel treatment arm. Treatment-related adverse events remained lower with Keytruda compared to docetaxel. Also reported at the ESMO 2016 Congress were health-related quality of life outcomes from the KEYNOTE-010 trial. Overall, from baseline to the 12-week assessment, patients treated with Keytruda reported numeric improvements, some of which were significant, in HRQoL and prolonged time to deterioration of lung cancer symptoms compared with docetaxel. Additionally, results from a third NSCLC abstract at the ESMO 2016 Congress explored, for the first time, the prevalence of PD-L1 in patients screened across multiple studies. The analysis assessed 4,784 patients with NSCLC who had tumors evaluable for PD-L1 expression and were screened for eligibility in three registrational studies of Keytruda -- KEYNOTE-001, KEYNOTE-010, and KEYNOTE-024. Based on this pooled analysis, 66 percent of patients across all three trials were determined to express PD-L1 and 28 percent were determined to have high levels of PD-L1 expression. These findings were similar across demographic and disease characteristics examined, including prior lines of therapy, age, tumor source, and histology.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

BAH

Booz Allen

$32.22

-0.67 (-2.04%)

08:00
06/26/17
06/26
08:00
06/26/17
08:00
Recommendations
Booz Allen analyst commentary  »

Booz Allen selloff an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 07

    Aug

SPGI

S&P Global

$146.70

1.32 (0.91%)

08:00
06/26/17
06/26
08:00
06/26/17
08:00
Options
S&P Global call buyer realizes 15% same-day gains »

Notable profits for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUTR

Cutera

$24.50

-0.2 (-0.81%)

07:59
06/26/17
06/26
07:59
06/26/17
07:59
Initiation
Cutera initiated  »

Cutera initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 30

    Jun

  • 28

    Sep

PM

Philip Morris

$119.56

-0.15 (-0.13%)

07:59
06/26/17
06/26
07:59
06/26/17
07:59
Hot Stocks
Philip Morris to invest additional EUR500M in heated tobacco facility in Italy »

Philip Morris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRUB

GrubHub

$47.70

1.37 (2.96%)

, AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

07:58
06/26/17
06/26
07:58
06/26/17
07:58
Downgrade
GrubHub, Amazon.com rating change  »

GrubHub downgraded to…

GRUB

GrubHub

$47.70

1.37 (2.96%)

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

07:57
06/26/17
06/26
07:57
06/26/17
07:57
Periodicals
Apple hires Stanford researcher for digital health, Digital Commerce 360 says »

Apple has hired Sumbul…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NBHC

National Bank

$31.55

-0.18 (-0.57%)

07:57
06/26/17
06/26
07:57
06/26/17
07:57
Hot Stocks
National Bank acquires Peoples in $143M transaction »

National Bank and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

PTLA

Portola Pharmaceuticals

$56.06

17.81 (46.56%)

07:56
06/26/17
06/26
07:56
06/26/17
07:56
Recommendations
Portola Pharmaceuticals analyst commentary  »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOXX

VOXX

$7.85

0.25 (3.29%)

07:55
06/26/17
06/26
07:55
06/26/17
07:55
Hot Stocks
Breaking Hot Stocks news story on VOXX »

VOXX trading halted, news…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEOT

Neothetics

$2.32

0.0501 (2.21%)

07:55
06/26/17
06/26
07:55
06/26/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Neothetics »

Neothetics trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATHM

Autohome

$45.47

-0.15 (-0.33%)

07:55
06/26/17
06/26
07:55
06/26/17
07:55
Conference/Events
Autohome to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NSU

Nevsun Resources

$2.27

-0.02 (-0.87%)

07:52
06/26/17
06/26
07:52
06/26/17
07:52
Hot Stocks
Nevsun Resources names Ian Pearce as Board Chair, effective June 30 »

Nevsun Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPLX

MPLX

$32.02

0.9 (2.89%)

07:52
06/26/17
06/26
07:52
06/26/17
07:52
Hot Stocks
MPLX sees FY17 net income $550M-$700M, adjusted EBITDA $1.7B-$1.85B »

Sees FY net cash provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

REGN

Regeneron

$517.33

-9.2 (-1.75%)

07:52
06/26/17
06/26
07:52
06/26/17
07:52
Downgrade
Regeneron rating change  »

Regeneron downgraded on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKBA

Akebia

$16.35

-0.14 (-0.85%)

07:52
06/26/17
06/26
07:52
06/26/17
07:52
Conference/Events
Akebia to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

, KHC

Kraft Heinz

$88.85

-0.25 (-0.28%)

07:49
06/26/17
06/26
07:49
06/26/17
07:49
Periodicals
Packaged food companies face pressure from Amazon's grocery plans, WSJ says »

Amazon's (AMZN) move…

AMZN

Amazon.com

$1,003.74

2.44 (0.24%)

KHC

Kraft Heinz

$88.85

-0.25 (-0.28%)

K

Kellogg

$70.56

0.15 (0.21%)

MDLZ

Mondelez

$44.90

0.05 (0.11%)

CPB

Campbell Soup

$53.58

-0.37 (-0.69%)

CAG

Conagra Brands

$37.23

0.14 (0.38%)

WFM

Whole Foods

$42.95

-0.255 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

COST

Costco

$157.13

-2.66 (-1.66%)

07:49
06/26/17
06/26
07:49
06/26/17
07:49
Technical Analysis
Technical View: Costco rises in pre-market, analyst action »

In the pre-market the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

ZTO

ZTO Express

$14.34

0.08 (0.56%)

07:48
06/26/17
06/26
07:48
06/26/17
07:48
Initiation
ZTO Express initiated  »

ZTO Express initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$31.73

-0.16 (-0.50%)

07:48
06/26/17
06/26
07:48
06/26/17
07:48
Recommendations
Micron analyst commentary  »

Micron multiple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

COH

Coach

$46.71

0.23 (0.49%)

07:47
06/26/17
06/26
07:47
06/26/17
07:47
Upgrade
Coach rating change  »

Coach upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCIT

NCI, Inc.

$20.40

-0.15 (-0.73%)

07:47
06/26/17
06/26
07:47
06/26/17
07:47
Recommendations
NCI, Inc. analyst commentary  »

NCI, Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$119.56

-0.15 (-0.13%)

07:47
06/26/17
06/26
07:47
06/26/17
07:47
Recommendations
Philip Morris analyst commentary  »

Philip Morris Q1 double…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JHG

Janus Henderson Group

$32.90

-0.19 (-0.57%)

07:45
06/26/17
06/26
07:45
06/26/17
07:45
Initiation
Janus Henderson Group initiated  »

Janus Henderson Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
06/26/17
06/26
07:45
06/26/17
07:45
General news
Treasury Market Outlook: bonds are mixed »

Treasury Market Outlook:…

KIN

Kindred Biosciences

$8.25

0.35 (4.43%)

07:44
06/26/17
06/26
07:44
06/26/17
07:44
Conference/Events
Kindred Biosciences to host business news update conference call »

Conference call to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 30

    Jun

  • 26

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.